502 related articles for article (PubMed ID: 16907853)
1. Effect of adamantylamide dipeptide as adjuvant therapy to praziquantel in mice infected with different S. mansoni isolates.
Botros S; Mahmoud M; Hammam O; Salah F; Zidek Z; Masek K
APMIS; 2006; 114(7-8):480-91. PubMed ID: 16907853
[TBL] [Abstract][Full Text] [Related]
2. Praziquantel efficacy in mice infected with PZQ non-susceptible S. mansoni isolate treated with artemether: parasitological, biochemical and immunohistochemical assessment.
Botros SS; Hammam O; Mahmoud M; Bergquist R
APMIS; 2010 Sep; 118(9):692-702. PubMed ID: 20718722
[TBL] [Abstract][Full Text] [Related]
3. Effect of adamantylamide dipeptide on reinfection resistance after primary infection eradication in experimental Schistosomiasis mansoni.
Botros S; Mahmoud S; Hassan S; Ibrahim A; Zidek Z; Masek K
Arzneimittelforschung; 1996 Jan; 46(1):74-8. PubMed ID: 8821522
[TBL] [Abstract][Full Text] [Related]
4. Response of Schistosoma mansoni isolates having different drug sensitivity to praziquantel over several life cycle passages with and without therapeutic pressure.
Sabra AN; Botros SS
J Parasitol; 2008 Apr; 94(2):537-41. PubMed ID: 18564758
[TBL] [Abstract][Full Text] [Related]
5. Validation of sensitivity to praziquantel using Schistosoma mansoni worm muscle tension and Ca2+-uptake as possible in vitro correlates to in vivo ED50 determination.
William S; Botros S
Int J Parasitol; 2004 Jul; 34(8):971-7. PubMed ID: 15217736
[TBL] [Abstract][Full Text] [Related]
6. Adult worm tegumental damage and egg-granulomas in praziquantel-resistant and -susceptible Schistosoma mansoni treated in vivo.
Liang YS; Coles GC; Dai JR; Zhu YC; Doenhoff MJ
J Helminthol; 2002 Dec; 76(4):327-33. PubMed ID: 12498638
[TBL] [Abstract][Full Text] [Related]
7. Potential antifibrotic effects of AT1 receptor antagonist, losartan, and/or praziquantel on acute and chronic experimental liver fibrosis induced by Schistosoma mansoni.
El-Lakkany NM; El-Maadawy W; Ain-Shoka A; Badawy A; Hammam O; Ebeid F
Clin Exp Pharmacol Physiol; 2011 Oct; 38(10):695-704. PubMed ID: 21762203
[TBL] [Abstract][Full Text] [Related]
8. Comparative efficacy and bioavailability of different praziquantel brands.
Botros S; El-Lakkany N; Seif el-Din SH; Sabra AN; Ibrahim M
Exp Parasitol; 2011 Feb; 127(2):515-21. PubMed ID: 21044626
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic effect of subcurative dose praziquantel on Schistosoma mansoni infected mice and resistance to challenge infection after treatment.
Chaiworaporn R; Maneerat Y; Rojekittikhun W; Ramasoota P; Janecharut T; Matsuda H; Kitikoon V
Southeast Asian J Trop Med Public Health; 2005 Jul; 36(4):846-52. PubMed ID: 16295535
[TBL] [Abstract][Full Text] [Related]
10. Drug-metabolizing enzymes and praziquantel bioavailability in mice harboring Schistosoma mansoni isolates of different drug susceptibilities.
Botros SS; El-Din SH; El-Lakkany NM; Sabra AN; Ebeid FA
J Parasitol; 2006 Dec; 92(6):1344-9. PubMed ID: 17304818
[TBL] [Abstract][Full Text] [Related]
11. Pharmacodynamics of pentoxifylline and/or praziquantel in murine schistosomiasis mansoni.
El-Lakkany N; Nosseir M
APMIS; 2007 Mar; 115(3):184-94. PubMed ID: 17367463
[TBL] [Abstract][Full Text] [Related]
12. Schistosoma mansoni eggs as a target for praziquantel: efficacy of oral application in mice.
Giboda M; Smith JM
J Trop Med Hyg; 1994 Apr; 97(2):98-102. PubMed ID: 8170010
[TBL] [Abstract][Full Text] [Related]
13. Parasitological and histo-pathological studies on schistosomiasis mansoni infected mice and treated with praziquatel and/or oltipraz.
Morsy GH
J Egypt Soc Parasitol; 2009 Aug; 39(2):687-701. PubMed ID: 19795775
[TBL] [Abstract][Full Text] [Related]
14. Determination of ED50 values for praziquantel in praziquantel-resistant and -susceptible Schistosoma mansoni isolates.
Cioli D; Botros SS; Wheatcroft-Francklow K; Mbaye A; Southgate V; Tchuenté LA; Pica-Mattoccia L; Troiani AR; El-Din SH; Sabra AN; Albin J; Engels D; Doenhoff MJ
Int J Parasitol; 2004 Jul; 34(8):979-87. PubMed ID: 15217737
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of avocado/soybean unsaponifiable alone or concurrently with praziquantel in murine schistosomiasis.
Soliman MF
Acta Trop; 2012 Jun; 122(3):261-6. PubMed ID: 22342904
[TBL] [Abstract][Full Text] [Related]
16. Susceptibility of a Brazilian wild rodent isolate of Schistosoma mansoni to praziquantel in mice.
Costa-Silva M; Barros Lde A; Garcia JS; Neves RH; Rodrigues-Silva R; Machado-Silva JR; Maldonado-Júnior A
Exp Parasitol; 2012 Apr; 130(4):394-9. PubMed ID: 22343042
[TBL] [Abstract][Full Text] [Related]
17. Enhancement of the therapeutic efficacy of praziquantel in murine Schistosomiasis mansoni using silica nanocarrier.
Tawfeek GM; Baki MHA; Ibrahim AN; Mostafa MAH; Fathy MM; Diab MSEDM
Parasitol Res; 2019 Dec; 118(12):3519-3533. PubMed ID: 31673833
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of an antipathology vaccine in murine schistosomiasis administered with and without chemotherapy.
Botros SS; Doughty BL; Shaker ZA; Akl MM; Sharmy R; Diab TM; Hassanein HI
Int J Immunopharmacol; 1996 Dec; 18(12):707-18. PubMed ID: 9172014
[TBL] [Abstract][Full Text] [Related]
19. Parasitological, hematological and ultrastructural study of the effect of COX-2 inhibitor, pyocyanin pigment and praziquantel, on S. mansoni infected mice.
Mohamed AH; Ezz El-Din N; Fahmy ZH; El-Shennawy AM; Hassan E
J Egypt Soc Parasitol; 2006 Apr; 36(1):197-220. PubMed ID: 16605111
[TBL] [Abstract][Full Text] [Related]
20. Short report: diminished susceptibility to praziquantel in a Senegal isolate of Schistosoma mansoni.
Fallon PG; Sturrock RF; Niang AC; Doenhoff MJ
Am J Trop Med Hyg; 1995 Jul; 53(1):61-2. PubMed ID: 7625534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
